None

By LOLITA BALDOR and FATIMA HUSSEIN WEST PALM BEACH, Fla. (AP) — President-elect Donald Trump said Wednesday that he has chosen Keith Kellogg, a highly decorated retired three-star general, to serve as his special envoy for Ukraine and Russia. Kellogg, who is one of the architects of a staunchly conservative policy book that lays out an “America First” national security agenda for the incoming administration, will come into the role as Russia’s invasion of Ukraine enters its third year in February. Trump made the announcement on his Truth Social account, and said “He was with me right from the beginning! Together, we will secure PEACE THROUGH STRENGTH, and Make America, and the World, SAFE AGAIN!” Kellogg, an 80 year-old retired Army lieutenant general who has long been Trump’s top adviser on defense issues, served as national security adviser to Vice President Mike Pence , was chief of staff of the National Security Council and then stepped in as an acting security adviser for Trump after Michael Flynn resigned. As special envoy for Ukraine and Russia, Kellogg will have to navigate an increasingly untenable war between the two nations. The Biden administration has begun urging Ukraine to quickly increase the size of its military by drafting more troops and revamping its mobilization laws to allow for the conscription of troops as young as 18. The White House has pushed more than $56 billion in security assistance to Ukraine since the start of Russia’s February 2022 invasion and expects to send billions more to Kyiv before Biden leaves office in less than months. Trump has criticized the billions that the Biden administration has poured into Ukraine. Washington has recently stepped up weapons shipments and has forgiven billions in loans provided to Kyiv. The incoming Republican president has said he could end the war in 24 hours, comments that appear to suggest he would press Ukraine to surrender territory that Russia now occupies. As a co-chairman of the American First Policy Institute’s Center for American Security, Kellogg wrote several of the chapters in the group’s policy book. The book, like the Heritage Foundation’s “Project 2025,” is a move to lay out a Trump national security agenda and avoid the mistakes of 2016 when he entered the White House largely unprepared. Kellogg in April wrote that “bringing the Russia-Ukraine war to a close will require strong, America First leadership to deliver a peace deal and immediately end the hostilities between the two warring parties.” Trump’s proposed national security advisor U.S. Rep. Michael Waltz (R-Fla.) tweeted Wednesday that “Keith has dedicated his life to defending our great country and is committed to bringing the war in Ukraine to a peaceful resolution.” Kellogg was a character in multiple Trump investigations dating to his first term. He was among the administration officials who listened in on the July 2019 call between Trump and Volodymyr Zelenskyy in which Trump prodded his Ukrainian counterpart to pursue investigations into the Bidens. The call, which Kellogg would later say did not raise any concerns on his end, was at the center of the first of two House impeachment cases against Trump, who was acquitted by the Senate both times. On Jan. 6, 2021, hours before pro-Trump rioters stormed the U.S. Capitol, Kellogg, who was then Pence’s national security adviser, listened in on a heated call in which Trump told his vice president to object or delay the certification in Congress of President Joe Biden ’s victory. He later told House investigators that he recalled Trump saying to Pence words to the effect of: “You’re not tough enough to make the call.” Baldor reported from Washington. AP writer Eric Tucker in Washington contributed to this report.Lake Oswego home of incoming Clackamas County commissioner served with search warrant, lawyer says

Anon Casino Review: The Autonomous, Anonymous Casino with No Borders, No Limits

COPPER MOUNTAIN, Colo. (AP) — For a pair of lower-level downhill events, this sure had plenty of Olympic medal-capturing and World Cup-winning ski racers. The stage belonged to Lindsey Vonn , the 40-year-old who took another step on her comeback trail Saturday with her first races in nearly six years. Vonn wasn't particularly speedy and finished in the middle of the pack on a cold but sunny day at Copper Mountain. Times and places weren't the mission, though, as much as getting used to the speed again and gaining the necessary points to compete on the World Cup circuit this season. Vonn accomplished both, finishing 24th in the first downhill race of the day and 27th in the second. She posted on social media after the FIS races that she had enough points to enter World Cup events. The timing couldn't be more perfect — the next stop on the women's circuit is Beaver Creek, Colorado, in a week. Vonn, who used to own a home in nearby Vail, hasn't committed to any sort of timetable for a World Cup return. “Today was a solid start and I had a blast being in start with my teammates again!” Vonn wrote on X . “While I’m sure people will speculate and say I’m not in top form because of the results, I disagree. This was training for me. I’m still testing equipment and getting back in the groove.” Her competition — a veritable who's who of high-profile ski racers — applauded her efforts. “I don't expect her to come back and win — just that she comes back and she has fun,” said Federica Brignone of Italy, a former overall World Cup champion and three-time Olympic medalist. “She's having fun, and she’s doing what she loves. That’s the best thing that she could do.” In the first race on a frigid morning, Vonn wound up 1.44 seconds behind the winning time of 1 minute, 5.79 seconds posted by Mirjam Puchner of Austria. In her second race through the course later in the morning, Vonn was 1.53 seconds behind Cornelia Huetter of Austria, who finished in 1:05.99. Huetter is the reigning season-long World Cup downhill champion. “It’s really nice to compare with her again, and nice to have her (racing) again,” Huetter said. “For sure, for the skiing World Cup, we have a lot of more attention. It's generally good for all racers because everyone is looking.” Also in the field were Nadia Delago of Italy, who won a bronze medal in downhill at the 2022 Beijing Olympics, and Puchner, the Olympic silver winner in super-G in Beijing. In addition, there was Marta Bassino of Italy, a winner of the super-G at the 2023 world championships, and two-time Olympic champion Michelle Gisin of Switzerland. “For me, it was really a training, but it was fun to have a World Cup race level right here,” Gisin said. “It was a crazy race.” Vonn remains a popular figure and took the time after each run to sign autographs for young fans along with posing for photos. When she left the sport, Vonn had 82 World Cup race victories, which stood as the record for a woman and within reach of the all-time Alpine record of 86 held by Swedish standout Ingemar Stenmark. The women’s mark held by Vonn was surpassed in January 2023 by Mikaela Shiffrin, who now has 99 wins — more than any Alpine ski racer in the history of the sport. Shiffrin is currently sidelined after a crash in a giant slalom event in Killington, Vermont , last weekend. Vonn’s last major race was in February 2019, when she finished third in a downhill during the world championships in Sweden. The three-time Olympic medalist left the circuit still near the top of her game. But all the broken arms and legs, concussions and torn knee ligaments took too big a toll and sent her into retirement. She had a partial knee replacement last April and felt good enough to give racing another shot. “It's very impressive to see all the passion that Lindsey still has,” Gisin said. Also racing Saturday was 45-year-old Sarah Schleper, who once competed for the United States but now represents Mexico. Schleper was the next racer behind Vonn and they got a chance to share a moment between a pair of 40-somethings still racing. “I was like, ‘Give me some tips, Lindsey,’” Schleper said. “She’s like, ‘Oh, it’s a highway tuck, the whole thing.’ Then she’s like, ‘It’s just like the good old days.’" AP skiing: https://apnews.com/hub/alpine-skiing

Congenital Hyperinsulinism Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Rezolute, Hanmi Pharmaceutical, Zealand Pharma, Crinetics Pharmaceuticals 11-27-2024 07:39 PM CET | Health & Medicine Press release from: DelveIinsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Congenital Hyperinsulinism pipeline constitutes 4+ key companies continuously working towards developing 6+ Congenital Hyperinsulinism treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Congenital Hyperinsulinism Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Congenital Hyperinsulinism Market. The Congenital Hyperinsulinism Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Congenital Hyperinsulinism Pipeline Report: https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Congenital Hyperinsulinism treatment therapies with a considerable amount of success over the years. •Congenital Hyperinsulinism companies working in the treatment market are Crinetics Pharmaceuticals, Hanmi Pharmaceutical, Rezolute, Zealand Pharma, and others, are developing therapies for the Congenital Hyperinsulinism treatment •Emerging Congenital Hyperinsulinism therapies in the different phases of clinical trials are- CRN-04777, HM 15136, RZ358, Dasiglucagon, and others are expected to have a significant impact on the Congenital Hyperinsulinism market in the coming years. •In October 2024, Zealand Pharma A/S (Nasdaq: ZEAL), a biotechnology company specializing in peptide-based medicines, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Part 1 of the New Drug Application (NDA) for dasiglucagon. This application is for the prevention and treatment of hypoglycemia in pediatric patients aged 7 days and older with congenital hyperinsulinism (CHI) for up to three weeks of dosing. •In September 2024, The US Food and Drug Administration (FDA) has removed the partial clinical holds on Rezolute's RZ358 (ersodetug), allowing the drug to proceed with a Phase III trial for the treatment of hypoglycemia caused by congenital hyperinsulinism (HI). This regulatory decision enables the inclusion of US participants in the ongoing global sunRIZE study. •In July 2024, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced today that it has acquired avexitide from Eiger BioPharmaceuticals, Inc. (Eiger). Avexitide has been investigated for its potential use in treating hyperinsulinemic hypoglycemia. Congenital Hyperinsulinism Overview Congenital Hyperinsulinism (CHI) is a rare genetic disorder characterized by the excessive production and secretion of insulin by the beta cells in the pancreas. Insulin is a hormone responsible for regulating blood sugar levels by promoting the uptake of glucose into cells. In individuals with congenital hyperinsulinism, there is an abnormality in the regulation of insulin secretion, leading to hypoglycemia (low blood sugar). Get a Free Sample PDF Report to know more about Congenital Hyperinsulinism Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/congenital-hyperinsulinism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging Congenital Hyperinsulinism Drugs Under Different Phases of Clinical Development Include: •CRN-04777: Crinetics Pharmaceuticals •HM 15136: Hanmi Pharmaceutical •RZ358: Rezolute •Dasiglucagon: Zealand Pharma Congenital Hyperinsulinism Route of Administration Congenital Hyperinsulinism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as •Oral •Parenteral •Intravenous •Subcutaneous •Topical Congenital Hyperinsulinism Molecule Type Congenital Hyperinsulinism Products have been categorized under various Molecule types, such as •Recombinant fusion proteins •Small molecule •Monoclonal antibody •Peptide •Polymer •Gene therapy Congenital Hyperinsulinism Pipeline Therapeutics Assessment •Congenital Hyperinsulinism Assessment by Product Type •Congenital Hyperinsulinism By Stage and Product Type •Congenital Hyperinsulinism Assessment by Route of Administration •Congenital Hyperinsulinism By Stage and Route of Administration •Congenital Hyperinsulinism Assessment by Molecule Type •Congenital Hyperinsulinism by Stage and Molecule Type DelveInsight's Congenital Hyperinsulinism Report covers around 6+ products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Congenital Hyperinsulinism product details are provided in the report. Download the Congenital Hyperinsulinism pipeline report to learn more about the emerging Congenital Hyperinsulinism therapies https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Congenital Hyperinsulinism Therapeutics Market include: Key companies developing therapies for Congenital Hyperinsulinism are - Zealand Pharma, Rezolute, Hanmi Pharmaceutical, Crinetics Pharmaceuticals, and others. Congenital Hyperinsulinism Pipeline Analysis: The Congenital Hyperinsulinism pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Congenital Hyperinsulinism with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Congenital Hyperinsulinism Treatment. •Congenital Hyperinsulinism key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Congenital Hyperinsulinism Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Congenital Hyperinsulinism market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Congenital Hyperinsulinism drugs and therapies https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Congenital Hyperinsulinism Pipeline Market Drivers •Increase in awareness of Congenital Hyperinsulinisms, increase in research and developmental activities are some of the important factors that are fueling the Congenital Hyperinsulinism Market. Congenital Hyperinsulinism Pipeline Market Barriers •However, high-cost associated with the disease, complications associated with insulin formulation and other factors are creating obstacles in the Congenital Hyperinsulinism Market growth. Scope of Congenital Hyperinsulinism Pipeline Drug Insight •Coverage: Global •Key Congenital Hyperinsulinism Companies: Crinetics Pharmaceuticals, Hanmi Pharmaceutical, Rezolute, Zealand Pharma, and others •Key Congenital Hyperinsulinism Therapies: CRN-04777, HM 15136, RZ358, Dasiglucagon, and others •Congenital Hyperinsulinism Therapeutic Assessment: Congenital Hyperinsulinism current marketed and Congenital Hyperinsulinism emerging therapies •Congenital Hyperinsulinism Market Dynamics: Congenital Hyperinsulinism market drivers and Congenital Hyperinsulinism market barriers Request for Sample PDF Report for Congenital Hyperinsulinism Pipeline Assessment and clinical trials https://www.delveinsight.com/sample-request/congenital-hyperinsulinism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Congenital Hyperinsulinism Report Introduction 2. Congenital Hyperinsulinism Executive Summary 3. Congenital Hyperinsulinism Overview 4. Congenital Hyperinsulinism- Analytical Perspective In-depth Commercial Assessment 5. Congenital Hyperinsulinism Pipeline Therapeutics 6. Congenital Hyperinsulinism Late Stage Products (Phase II/III) 7. Congenital Hyperinsulinism Mid Stage Products (Phase II) 8. Congenital Hyperinsulinism Early Stage Products (Phase I) 9. Congenital Hyperinsulinism Preclinical Stage Products 10. Congenital Hyperinsulinism Therapeutics Assessment 11. Congenital Hyperinsulinism Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Congenital Hyperinsulinism Key Companies 14. Congenital Hyperinsulinism Key Products 15. Congenital Hyperinsulinism Unmet Needs 16 . Congenital Hyperinsulinism Market Drivers and Barriers 17. Congenital Hyperinsulinism Future Perspectives and Conclusion 18. Congenital Hyperinsulinism Analyst Views 19. Appendix 20. About DelveInsight Related Reports: Congenital Hyperinsulinism Market https://www.delveinsight.com/report-store/congenital-hyperinsulinism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Congenital Hyperinsulinism Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Congenital Hyperinsulinism Epidemiology https://www.delveinsight.com/report-store/congenital-hyperinsulinism-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Congenital Hyperinsulinism Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Latest Reports by DelveInsight •Cervical Dysplasia Market: https://www.delveinsight.com/report-store/cervical-dysplasia-market-insights •Hypogonadism Market: https://www.delveinsight.com/report-store/hypogonadism-market •Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market •Non-hodgkin's Lymphoma Market: https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-market •Substance Use Disorder Market: https://www.delveinsight.com/report-store/substance-use-disorder-market •Transcatheter Heart Valve Replacement Devices Market: https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market •Bone Neoplasms Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market •Peak Flow Meters Market: https://www.delveinsight.com/report-store/peak-flow-meters-market Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.

Former NJ senator Menendez seeks new trial, says error tainted convictionRussia-Ukraine escalation fears push oil and defence stocks higher